Priothera
Manufacturing · Ireland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
88 Harcourt Dublin 2 St, Dublin, Dublin ...Website
www.priothera.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Priothera
Priothera is a late-stage biopharma company pioneering the development of mocravimod, a potential new standard of care in hematologic cancers, in addition to cellular therapies such as hematopoietic cell transplantation and CAR-T cell therapies.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Priothera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Priothera, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Priothera recently announced quarterly report
Check if Priothera has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Priothera launches new products
Funding: Get notified immidiatlly once Priothera has new funding data
Congratulate Masked Content for being promoted to Masked Content at Priothera
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Priothera is spiking on competitors!
Click to see if Priothera had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Priothera as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Priothera is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Priothera is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Priothera.
Priothera financials insights
Gather financial insights about Priothera, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$35.4M
2025
Other Financing Round
$2M
Priothera Tech Stack
A closer look at the technologies used by Priothera
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Sales, Search, Software, Doctors / Physicians, Medical Research, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Operations, Healthcare Technology, Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
New Hire
Executive Move
Executive Moves, New Hire
Priothera News & Media
Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program
Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical ProgramPriothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen
Highly experienced clinical development executive joins Priothera Board as mocravimod progresses through global Phase 3 trial as adjunctive and maintenance treatment in AML patients undergoing allo-HCTPriothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML)
Dr. Hasskarl to lead global Phase 3 MO-TRANS study evaluating mocravimod as an adjunctive treatment to allo-HCT in AMLPriothera to Present Trial in Progress Poster for Mocravimod at 2024 American Society of Hematology (ASH) Annual Meeting
Mocravimod is being investigated in a global MO-TRANS Phase 3 study in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation Mocravimod is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Priothera
Sign Up For FreeTo access detailed company insights
Priothera is a late-stage biopharma company pioneering the development of mocravimod, a potential new standard of care in hematologic cancers, in addition to cellular therapies such as hematopoietic cell transplantation and CAR-T cell therapies.... Read More
